Where does Mallinckrodt Pharmaceuticals Ireland Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Mallinckrodt Pharmaceuticals Ireland Limited ranks #7,299 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Mallinckrodt Pharmaceuticals Ireland Limited hold?

Mallinckrodt Pharmaceuticals Ireland Limited holds 45 US utility patents granted between 2021 and 2025, spanning 19 technology areas.

What is Mallinckrodt Pharmaceuticals Ireland Limited's Innovation Score?

Mallinckrodt Pharmaceuticals Ireland Limited has an Innovation Score of 55.7 out of 100 (top 7% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Mallinckrodt Pharmaceuticals Ireland Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Mallinckrodt Pharmaceuticals Ireland Limited.

What does claim depth mean for Mallinckrodt Pharmaceuticals Ireland Limited's patents?

Mallinckrodt Pharmaceuticals Ireland Limited's patents average 11.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Mallinckrodt Pharmaceuticals Ireland Limited

Q: What technology areas does Mallinckrodt Pharmaceuticals Ireland Limited focus on?

Mallinckrodt Pharmaceuticals Ireland Limited's top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 30 patents, ranking #239 of 3,490 assignees active in that subclass. Grants appear in 19 CPC subclasses total.

Q: How is the Mallinckrodt Pharmaceuticals Ireland Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 45 granted patents across 19 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Mallinckrodt ranks #7,299 of 49,997 tracked US assignees by granted-patent volume, with 45 patents across 19 technology areas.

#7,299
of 49,997 US assignees by volume: Top 7%
by Innovation Score (55.7/100): 11.7
avg claims per patent

USPTO PatentsView assignee plate

Corpus R7299 · Foreign Corporation #7,299 · 45 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 45 grants
UPPER-Q #7,299/49,997
PHOTO-FINISH Magna Powertrain of…
CPC-FOCUS A61M · 19 areas
INNOV-PAR 55.7/100
CLAIMS-PAR 11.7 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Magna Powertrain of America, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Mallinckrodt’s 55.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.2 pts (24%) Velocity 20.0 pts (36%) Breadth 15.4 pts (28%) Claim depth 7.0 pts (13%)

Qualcomm Incorporated · highest

85
Heraeus Quarzglas & KG · near

56
Mallinckrodt… · this assignee

56
Smith International · near

56
Andersen · near

56
Livsmed · near

56
3D Lighting… · lowest

7

What this shows Mallinckrodt's Innovation Score is 55.7/100 (top 7% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Mallinckrodt?

Each dot is one of Mallinckrodt’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Mallinckrodt’s own 11.7 claims/patent is at or below the 17.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Mallinckrodt vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Mallinckrodt's grants concentrate

Mallinckrodt Pharmaceuticals Ireland Limited is a focused PatentsView assignee: 19 CPC subclasses with 66.7% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2022 (11 grants) versus a trough of 6 in 2023. By volume, Mallinckrodt sits between Medimop Medical Projects Ltd. and Moogsoft Inc..

Mallinckrodt's three-year grant acceleration

Mallinckrodt Pharmaceuticals Ireland Limited shows 24 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Medimop Medical P…

45
Movea

45
MY JOB Matcher

45
Magna Powertrain…

45
Mapquest

45
Mexichem Amanco H…

45
Microvast Power S…

45
Moogsoft

45
Mallinckrodt Phar… ◀

45

What this shows Mallinckrodt holds 45 patents at rank #7,299, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Mallinckrodt

By rank, the assignees closest to #7,299 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Mallinckrodt's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Mallinckrodt, neither rank-band nor same-CPC leaders (those blocks stay above). In A61M (Devices FOR Introducing Media Into), Mallinckrodt ranks #239 of 3,490 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (56 here).

Heraeus Quarzglas GMBH & Co. KG 56 Smith International, Inc. 56 Livsmed Inc. 56 Andersen Corporation 56

Mallinckrodt's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

56 Top 7% higher than 93% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Mallinckrodt Pharmaceuticals Ireland Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	7	15.6%
2022	11	24.4%
2023	6	13.3%
2024	7	15.6%
2025partial year	14	31.1%

Which technologies does Mallinckrodt Pharmaceuticals Ireland Limited patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 30

G01F - Measuring Volume, Volume Flow, Mass Flow OR Liquid LEVEL; Metering BY Volume 11

F17C - Vessels FOR Containing OR Storing Compressed, Liquefied OR Solidified GASES; Fixed-capacity GAS-HOLDERS; Filling Vessels With, OR Discharging From Vessels, Compressed, Liquefied, OR Solidified Gases 7

B63C - Launching, Hauling-out, OR Dry-docking OF VESSELS; Life-saving IN WATER; Equipment FOR Dwelling OR Working Under WATER; Means FOR Salvaging OR Searching FOR Underwater Objects 7

A61B - DIAGNOSIS; SURGERY; Identification 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

B01D - Separation 6

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

C01B - Non-metallic ELEMENTS; Compounds THEREOF; ; Metalloids OR Compounds Thereof NOT Covered BY Subclass C01c 3

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 3

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

Top 15 of 19 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Mallinckrodt Pharmaceuticals Ireland Limited's patent record in context - here's where to go next.

Mallinckrodt Pharmaceuticals Ireland Limited's lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 66.7% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #7,299 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Mallinckrodt Pharmaceuticals Ireland Limited against Medimop Medical Projects Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 55.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.